Nanophotonics has emerged as a transformative field that is offering innovative solutions at the intersection of nanotechnology and photonics. This cutting-edge technology involves the manipulation of light at the nanoscale, enabling precise control over the interaction between light and matter. In the realm of pharmaceuticals, nanophotonics holds significant promise for drug delivery, diagnostics, and therapeutic interventions. The use of nanophotonic materials, such as plasmonic nanoparticles, allows for enhanced imaging modalities and targeted drug delivery systems. These nano-sized structures can be engineered to interact with specific biological targets, providing unprecedented accuracy in drug distribution and minimizing side effects.
Additionally, nanophotonics facilitates the development of advanced biosensors for real-time monitoring of biochemical processes, enabling personalized medicine approaches. As the pharmaceutical industry continues to explore the potential of nanophotonics, the convergence of these fields is poised to revolutionize drug development and healthcare, paving the way for more effective and tailored therapeutic interventions.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia